Clinical Trial: Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma/stem Cells (AdMSC) Transplantation in Patients with Critical Limb Ischemia.

U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06795620) titled 'Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma/stem Cells (AdMSC) Transplantation in Patients with Critical Limb Ischemia.' on Dec. 16, 2024.

Brief Summary: Critical limb ischemia (CLI) is the most severe stage of peripheral arterial disease (PAD). Cell therapy delivered to the ischemic muscle constitutes a promising approach to treat CLI patients with no or poor options of vascularization. Pre-clinical study and clinical phase I have demonstrated the safety and feasibility of the use of autologous AdMSC treatment in patients without option for revascularization CLI patients and encouraging preliminary ef...